(Q36857537)

16 August 2017

1 reference

title

PPARgamma agonists: safety issues in heart failure (English)

1 reference

16 August 2017

0 references

W H Wilson Tang

1

1 reference

PubMed ID

17587386

16 August 2017

Anjli Maroo

series ordinal

2

1 reference

16 August 2017

1 July 2007

1 reference

Diabetes, Obesity and Metabolism

16 August 2017

1 reference

16 August 2017

9

1 reference

16 August 2017

4

1 reference

16 August 2017

447-454

1 reference

Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets

16 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Significant weight gain with rezulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Pulmonary edema associated with rosiglitazone and troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Possible heart failure exacerbation associated with rosiglitazone: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Pioglitazone-induced heart failure despite normal left ventricular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Pioglitazone initiation and subsequent hospitalization for congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Enhanced hypothalamic AMP-activated protein kinase activity contributes to hyperphagia in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Glycemic control and heart failure among adult patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Management of rosiglitazone-induced edema: two case reports and a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Unilateral edema due to a thiazolidinedione

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Thiazolidinedione-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Thiazolidinediones and congestive heart failure-exacerbation or new onset of left ventricular dysfunction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Pulmonary edema associated with troglitazone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

Heart Failure Prevalence, Incidence, and Mortality in the Elderly With Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00616.X

10.1111/J.1463-1326.2006.00616.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17587386